BIOS Capital Management LP Takes Position in IN8bio, Inc. (NASDAQ:INAB)

BIOS Capital Management LP bought a new stake in IN8bio, Inc. (NASDAQ:INAB) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,600,001 shares of the company’s stock, valued at approximately $2,212,000. IN8bio makes up about 2.3% of BIOS Capital Management LP’s investment portfolio, making the stock its 6th biggest holding. BIOS Capital Management LP owned 11.87% of IN8bio at the end of the most recent quarter.

Separately, Sigma Planning Corp grew its holdings in shares of IN8bio by 42.0% in the third quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after purchasing an additional 251,600 shares in the last quarter. 92.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright cut their target price on shares of IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a report on Friday.

IN8bio Trading Down 0.4 %

INAB stock opened at $0.23 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a fifty day moving average price of $0.28 and a 200 day moving average price of $0.30. The firm has a market cap of $18.32 million, a PE ratio of -0.30 and a beta of 0.03. IN8bio, Inc. has a fifty-two week low of $0.21 and a fifty-two week high of $1.74.

IN8bio (NASDAQ:INAB) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Sell-side analysts anticipate that IN8bio, Inc. will post -0.56 earnings per share for the current fiscal year.

IN8bio Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.